Bioengineered vascular access maintains structural integrity in response to arteriovenous flow and repeated needle puncture

Bryan W. Tillman, Saami K. Yazdani, Lucas P. Neff, Matthew A. Corriere, George J. Christ, Shay Soker, Anthony Atala, Randolph L. Geary, James J. Yoo

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Tissue-engineered blood vessels (TEBV) have been proposed as an alternative to prosthetic grafts for dialysis access. However, arteriovenous (AV) grafts must withstand extreme flow rates and frequent needle trauma. In a proof-of-concept study, we sought to determine whether scaffold-based TEBV could withstand the hemodynamic and mechanical challenges of chronic dialysis access. TEBV were constructed using decellularized arterial scaffolds seeded with autologous ovine endothelial cells (EC) derived from circulating endothelial progenitor cells (EPC) using a novel high-affinity capture approach. Seeded scaffolds were preconditioned to arterial pressure and flow in a bioreactor for 2 weeks prior to implantation to create carotid artery to jugular vein AV grafts in each animal. TEBV were healed for 1 month before initiating percutaneous needle puncture 3 days/week. TEBV wall geometry and patency were monitored using duplex imaging and were either explanted for histologic analysis at 2 months (n = 5) or followed for up to 6 months until venous outflow stenosis threatened AV graft patency (n = 6). Despite high flow, TEBV maintained stable geometry with only modest wall dilation (under 6%) by 4 months after implantation. Needle access was well tolerated with a single puncture site complication, a small pseudoaneurysm, occurring in the late group. Time-to-hemostasis at puncture sites averaged 4 ± 2 minutes. Histologic analysis at 2 months demonstrated repopulation of the outer TEBV wall by host cells and healing of needle punctures by cellular ingrowth and new matrix deposition along the tract. TEBV followed beyond 2 months showed stable wall geometry but, consistent with the primary mode of clinical AV graft failure, all TEBV eventually developed venous anastomotic stenosis (mean, 4.4 ± 0.9 months; range, 3.3-5.6 months postimplantation; n = 6). This pilot study supports the concept of creating dialysis access from scaffold-based autologous TEBV. Engineered AV grafts were created within a clinically relevant time frame and demonstrated stable wall geometry despite high flow and repeated puncture. Cellular ingrowth and puncture site healing may improve wall durability, but venous outflow stenosis remains the primary mode of TEBV graft failure in the ovine model.

Original languageEnglish
Pages (from-to)783-793
Number of pages11
JournalJournal of Vascular Surgery
Volume56
Issue number3
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Punctures
Needles
Blood Vessels
Transplants
Dialysis
Pathologic Constriction
Sheep
Tissue Scaffolds
False Aneurysm
Jugular Veins
Bioreactors
Hemostasis
Carotid Arteries
Cell Wall
Dilatation
Arterial Pressure
Endothelial Cells
Hemodynamics
Wounds and Injuries

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Tillman, B. W., Yazdani, S. K., Neff, L. P., Corriere, M. A., Christ, G. J., Soker, S., ... Yoo, J. J. (2012). Bioengineered vascular access maintains structural integrity in response to arteriovenous flow and repeated needle puncture. Journal of Vascular Surgery, 56(3), 783-793. https://doi.org/10.1016/j.jvs.2012.02.030

Bioengineered vascular access maintains structural integrity in response to arteriovenous flow and repeated needle puncture. / Tillman, Bryan W.; Yazdani, Saami K.; Neff, Lucas P.; Corriere, Matthew A.; Christ, George J.; Soker, Shay; Atala, Anthony; Geary, Randolph L.; Yoo, James J.

In: Journal of Vascular Surgery, Vol. 56, No. 3, 01.09.2012, p. 783-793.

Research output: Contribution to journalArticle

Tillman, BW, Yazdani, SK, Neff, LP, Corriere, MA, Christ, GJ, Soker, S, Atala, A, Geary, RL & Yoo, JJ 2012, 'Bioengineered vascular access maintains structural integrity in response to arteriovenous flow and repeated needle puncture', Journal of Vascular Surgery, vol. 56, no. 3, pp. 783-793. https://doi.org/10.1016/j.jvs.2012.02.030
Tillman, Bryan W. ; Yazdani, Saami K. ; Neff, Lucas P. ; Corriere, Matthew A. ; Christ, George J. ; Soker, Shay ; Atala, Anthony ; Geary, Randolph L. ; Yoo, James J. / Bioengineered vascular access maintains structural integrity in response to arteriovenous flow and repeated needle puncture. In: Journal of Vascular Surgery. 2012 ; Vol. 56, No. 3. pp. 783-793.
@article{a87d38ba1fb34288929020c98366b61a,
title = "Bioengineered vascular access maintains structural integrity in response to arteriovenous flow and repeated needle puncture",
abstract = "Tissue-engineered blood vessels (TEBV) have been proposed as an alternative to prosthetic grafts for dialysis access. However, arteriovenous (AV) grafts must withstand extreme flow rates and frequent needle trauma. In a proof-of-concept study, we sought to determine whether scaffold-based TEBV could withstand the hemodynamic and mechanical challenges of chronic dialysis access. TEBV were constructed using decellularized arterial scaffolds seeded with autologous ovine endothelial cells (EC) derived from circulating endothelial progenitor cells (EPC) using a novel high-affinity capture approach. Seeded scaffolds were preconditioned to arterial pressure and flow in a bioreactor for 2 weeks prior to implantation to create carotid artery to jugular vein AV grafts in each animal. TEBV were healed for 1 month before initiating percutaneous needle puncture 3 days/week. TEBV wall geometry and patency were monitored using duplex imaging and were either explanted for histologic analysis at 2 months (n = 5) or followed for up to 6 months until venous outflow stenosis threatened AV graft patency (n = 6). Despite high flow, TEBV maintained stable geometry with only modest wall dilation (under 6{\%}) by 4 months after implantation. Needle access was well tolerated with a single puncture site complication, a small pseudoaneurysm, occurring in the late group. Time-to-hemostasis at puncture sites averaged 4 ± 2 minutes. Histologic analysis at 2 months demonstrated repopulation of the outer TEBV wall by host cells and healing of needle punctures by cellular ingrowth and new matrix deposition along the tract. TEBV followed beyond 2 months showed stable wall geometry but, consistent with the primary mode of clinical AV graft failure, all TEBV eventually developed venous anastomotic stenosis (mean, 4.4 ± 0.9 months; range, 3.3-5.6 months postimplantation; n = 6). This pilot study supports the concept of creating dialysis access from scaffold-based autologous TEBV. Engineered AV grafts were created within a clinically relevant time frame and demonstrated stable wall geometry despite high flow and repeated puncture. Cellular ingrowth and puncture site healing may improve wall durability, but venous outflow stenosis remains the primary mode of TEBV graft failure in the ovine model.",
author = "Tillman, {Bryan W.} and Yazdani, {Saami K.} and Neff, {Lucas P.} and Corriere, {Matthew A.} and Christ, {George J.} and Shay Soker and Anthony Atala and Geary, {Randolph L.} and Yoo, {James J.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.jvs.2012.02.030",
language = "English",
volume = "56",
pages = "783--793",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Bioengineered vascular access maintains structural integrity in response to arteriovenous flow and repeated needle puncture

AU - Tillman, Bryan W.

AU - Yazdani, Saami K.

AU - Neff, Lucas P.

AU - Corriere, Matthew A.

AU - Christ, George J.

AU - Soker, Shay

AU - Atala, Anthony

AU - Geary, Randolph L.

AU - Yoo, James J.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Tissue-engineered blood vessels (TEBV) have been proposed as an alternative to prosthetic grafts for dialysis access. However, arteriovenous (AV) grafts must withstand extreme flow rates and frequent needle trauma. In a proof-of-concept study, we sought to determine whether scaffold-based TEBV could withstand the hemodynamic and mechanical challenges of chronic dialysis access. TEBV were constructed using decellularized arterial scaffolds seeded with autologous ovine endothelial cells (EC) derived from circulating endothelial progenitor cells (EPC) using a novel high-affinity capture approach. Seeded scaffolds were preconditioned to arterial pressure and flow in a bioreactor for 2 weeks prior to implantation to create carotid artery to jugular vein AV grafts in each animal. TEBV were healed for 1 month before initiating percutaneous needle puncture 3 days/week. TEBV wall geometry and patency were monitored using duplex imaging and were either explanted for histologic analysis at 2 months (n = 5) or followed for up to 6 months until venous outflow stenosis threatened AV graft patency (n = 6). Despite high flow, TEBV maintained stable geometry with only modest wall dilation (under 6%) by 4 months after implantation. Needle access was well tolerated with a single puncture site complication, a small pseudoaneurysm, occurring in the late group. Time-to-hemostasis at puncture sites averaged 4 ± 2 minutes. Histologic analysis at 2 months demonstrated repopulation of the outer TEBV wall by host cells and healing of needle punctures by cellular ingrowth and new matrix deposition along the tract. TEBV followed beyond 2 months showed stable wall geometry but, consistent with the primary mode of clinical AV graft failure, all TEBV eventually developed venous anastomotic stenosis (mean, 4.4 ± 0.9 months; range, 3.3-5.6 months postimplantation; n = 6). This pilot study supports the concept of creating dialysis access from scaffold-based autologous TEBV. Engineered AV grafts were created within a clinically relevant time frame and demonstrated stable wall geometry despite high flow and repeated puncture. Cellular ingrowth and puncture site healing may improve wall durability, but venous outflow stenosis remains the primary mode of TEBV graft failure in the ovine model.

AB - Tissue-engineered blood vessels (TEBV) have been proposed as an alternative to prosthetic grafts for dialysis access. However, arteriovenous (AV) grafts must withstand extreme flow rates and frequent needle trauma. In a proof-of-concept study, we sought to determine whether scaffold-based TEBV could withstand the hemodynamic and mechanical challenges of chronic dialysis access. TEBV were constructed using decellularized arterial scaffolds seeded with autologous ovine endothelial cells (EC) derived from circulating endothelial progenitor cells (EPC) using a novel high-affinity capture approach. Seeded scaffolds were preconditioned to arterial pressure and flow in a bioreactor for 2 weeks prior to implantation to create carotid artery to jugular vein AV grafts in each animal. TEBV were healed for 1 month before initiating percutaneous needle puncture 3 days/week. TEBV wall geometry and patency were monitored using duplex imaging and were either explanted for histologic analysis at 2 months (n = 5) or followed for up to 6 months until venous outflow stenosis threatened AV graft patency (n = 6). Despite high flow, TEBV maintained stable geometry with only modest wall dilation (under 6%) by 4 months after implantation. Needle access was well tolerated with a single puncture site complication, a small pseudoaneurysm, occurring in the late group. Time-to-hemostasis at puncture sites averaged 4 ± 2 minutes. Histologic analysis at 2 months demonstrated repopulation of the outer TEBV wall by host cells and healing of needle punctures by cellular ingrowth and new matrix deposition along the tract. TEBV followed beyond 2 months showed stable wall geometry but, consistent with the primary mode of clinical AV graft failure, all TEBV eventually developed venous anastomotic stenosis (mean, 4.4 ± 0.9 months; range, 3.3-5.6 months postimplantation; n = 6). This pilot study supports the concept of creating dialysis access from scaffold-based autologous TEBV. Engineered AV grafts were created within a clinically relevant time frame and demonstrated stable wall geometry despite high flow and repeated puncture. Cellular ingrowth and puncture site healing may improve wall durability, but venous outflow stenosis remains the primary mode of TEBV graft failure in the ovine model.

UR - http://www.scopus.com/inward/record.url?scp=84865254046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865254046&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2012.02.030

DO - 10.1016/j.jvs.2012.02.030

M3 - Article

VL - 56

SP - 783

EP - 793

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 3

ER -